A possible injury in the non-hormonal AVP system in Alzheimer's disease has been suggested by the recent finding of a reduced AVP concentration in CSF and in brain tissue.1-4 A decrease in plasma hormonal AVP has been also reported, suggesting damage as well to the hypothalamic magnocellular neurons and/or the neurotransmitters controlling the secretion of hormonal AVP.4
A possible injury in the non-hormonal AVP system in Alzheimer's disease has been suggested by the recent finding of a reduced AVP concentration in CSF and in brain tissue.1-4 A decrease in plasma hormonal AVP has been also reported, suggesting damage as well to the hypothalamic magnocellular neurons and/or the neurotransmitters controlling the secretion of hormonal AVP. 4 The main mechanisms controlling hypothalamic AVP secretion"6 are changes in blood osmolality and decrease in blood pressure and/or blood volume. An increase in blood osmolality is sensed by the osmoreceptor sited in the anterior hypothalamus. Impulses are carried from osmoreceptors to vasopressinergic neurons along cholinergic pathways. A decrease in blood pressure stimulates the highpressure carotid baroreceptor which, in turn, releases AVP through noradrenergic and cholinergic pathways; impulses are carried by the glossopharyngeal nerves to the brain stem, nucleus tractus solitarius, locus coeruleus and paraventricular and supraoptic nuclei. 6 Changes in blood volume act on the cardiopulmonary baroreceptors which stimulate AVP release through the cervical vagal pathways and the cholinergic synapses to the hypothalamus. Here, the cholinergic input from the low-pressure volume baroreceptors subserves a tonic excitatory action.7 8 AVP has also been found in other areas of the brain, where it is thought to play a non hormonal role acting as a neurotransmitter.1 4 AVP released in the cerebrospinal fluid (CSF-AVP) seems to originate from extra hypothalamic areas. The non-hormonal nature of CSF-AVP is confirmed by the findings of normal CSF-AVP levels in patients with severe neurogenic diabetes insipidus and by the fact that CSF-AVP does not increase after the osmolar or the baroreceptor mediated stimulation. Finally, CSF-AVP displays a circadian rhythm which is absent in plasma AVP.4 5011
The purpose of the present study was to evaluate the function of the hypothalamic cells secreting AVP in Alzheimer's disease. Thus, we evaluated AVP response both to changes in plasma osmolality and blood pressure and to metoclopramide."2 13
Patients and methods Our study concerned 10 tion in mean arterial pressure both in patients and controls. As shown in fig 1, where for clarity the results of five out of 10 patients are reported, AVP release was within the range of normality in all patients studied. The heart rate increase was also similar in both groups (data not reported).
A VP response to hypertonic saline infusion In control subjects the rise in AVP after saline challenge was significantly related to plasma osmolality (pOsm) increase. The regression line between AVP on the ordinate and pOsm on the abscisse was as follows: AVP (pg/ml) = 0-23 pOsm -64-63; r = 0-92 (p < 0-01). The mean "sensitivity" (slope) was 0-23, 0-02 and the mean responsiveness ("threshold") was 281, 3 mmol/kg. In Alzheimer patients the response was quite variable (table 2 and Haemodynamic and A VP responses to metoclopramide After metoclopramide injection, control subjects showed a rise in plasma vasopressin that was significant at 10 minutes (p < 0 01) and peaked at 30 minutes (p < 0-01). Plasma vasopressin then decreased and returned to base levels at 60 minutes. AVP response to metoclopramide was completely absent in patients with Alzheimer's disease (p < 0-01 vs controls at times + 10, + 20, + 30 min). Plasma osmolality, blood pressure and heart rate did not change in any of the subjects studied ( fig 6) .
Discussion
Our results showed that Alzheimer patients had an impaired response to osmotic stimuli and were unable to release AVP after metoclopramide. 
